Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1439-1450

  Janssen, Samuel ^a   Jakobsen, Carsten M ^b   Rosen, D Marc ^a   Ricklis, Rebecca M ^a   Reineke, Ulrich ^c   Christensen, Soeren B ^b   Lilja, Hans ^d   Denmeade, Samuel R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Jerini AG   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANTINEOPLASTIC AGENT; CALCIUM ION; CATHEPSIN B; CATHEPSIN D; ENZYME INHIBITOR; GLYCYLGLYCYLGLYCYLLYSYLALANYLARGINYLARGINYLLEUCINE; GLYCYLGLYCYLLYSYLALANYLHISTIDYLARGINYLLEUCINE; GLYCYLHISTIDYLGLUTAMYLLYSYLARGINYLARGINYLLEUCYLGLUTAMIC ACID; GLYCYLLYSYLALANYLPHENYLALANYLARGINYLARGININE 8 O [12 (LEUCINOYLAMINO)DODECANOYL] 8 O DEBUTANOYLTHAPSIGARGIN; GLYCYLLYSYLALANYLPHENYLALANYLARGINYLARGINYLLEUCINE; GLYCYLSERYLLYSYLGLYCYLHISTIDYLPHENYLALANYLHISTIDYLLEUCINE; GLYCYLSERYLLYSYLGLYCYLHISTIDYLPHENYLALANYLLYSYLLEUCINE; GLYCYLSERYLLYSYLGLYCYLPROLYLPHENYLALANYLLYSYLLEUCINE; KALLIKREIN; MORPHOLINOCARBONYL GLYCYLLYSYLALANYLPHENYLALANYLARGININE 7 AMINO 4 METHYLCOUMARIN; NITROTYROSINE GLYCYLLYSYLALANYLARGINYLALANYLPHENYLALANINE DIAMINOPROPIONIC ACID PHENYLALANYLLYSINE; NITROTYROSINE GLYCYLLYSYLALANYLLYSYLPROLYLARGININE DIAMINOPROPIONIC ACID PHENYLALANYLLYSINE; NITROTYROSINE GLYCYLLYSYLALANYLMETHIONYLARGINYLGLUTAMINE DIAMINOPROPIONIC ACID PHENYLALANYLLYSINE; NITROTYROSINE GLYCYLLYSYLALANYLPHENYLALANYLARGINYLARGININE DIAMINOPROPIONIC ACID GLYCYLLYSINE; NITROTYROSINE GLYCYLLYSYLALANYLPHENYLALANYLARGINYLARGININE DIAMINOPROPIONIC ACID PHENYLALANYLLYSINE; NITROTYROSINE GLYCYLLYSYLALANYLPHENYLALANYLARGINYLARGINYLLEUCYLGLYCYLLYSINE; NITROTYROSINE GLYCYLLYSYLALANYLPHENYLALANYLARGINYLLEUCINE DIAMINOPROPIONIC ACID PHENYLALANYLLYSINE; NITROTYROSINE GLYCYLSERYLLYSYLGLYCYLHISTIDYLPHENYLALANYLLYSYLLEUCINE DIAMINOPROPIONIC ACID PHENYLALANYLLYSINE; PLASMIN; PRODRUG; PROLYLPHENYLALANYLARGININE 7 AMINO 4 METHYLCOUMARIN; THAPSIGARGIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG HYDROLYSIS; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN HYDROLYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSIN B; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROLYSIS; MALE; MICE; MOLECULAR STRUCTURE; PEPTIDE LIBRARY; PEPTIDES; PRODRUGS; PROSTATIC NEOPLASMS; SUBSTRATE SPECIFICITY; THAPSIGARGIN; TISSUE KALLIKREINS; TRYPSIN;

EID: 9444268199     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G(O)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001;61:6372-6.
2. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-80.
3. Rasmussen U, Brogger Christensen S, Sandberg F. Thapsigargine and thapsigargicine, two new histamine liberators from Thapsia grarganica L. Acta Pharm Suec 1978;15:133-40.
4. 2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+ -ATPase. Proc Natl Acad Sci U S A 1990;87:2466-70.
5. Davidson GA, Varhol RJ. Kinetics of thapsigargin-Ca(2+)-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J Biol Chem 1995;270:11731-4.
6. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994;54:6167-75.
7. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 1997;33:201-7.
8. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990-1000.
9. Jackisch C, Hahm HA, Tombal B, et al. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res 2000;6:2844-50.
10. Denmeade SR, Isaacs JT. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer J Sci Am 1998;4 Suppl 1:S15-21.
11. Lilja H, Piironen T, Rittenhouse H, Mikolajczyk S, Slawin K. Prostate-specific Antigen. In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, Miles BJ, editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 638-50.
12. Deperthes D, Chapdelaine P, Tremblay RR, et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995;1245:311-6.
13. Diamandis EP, Yousef GM, Clements J, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855-8.
14. Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
15. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1-6.
16. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
17. Akiyama K, Nakamura T, Iwanaga S, Hara M. The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett 1987;225:168-72.
18. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
19. 2-macroglobulin receptor/LDL receptor-related protein. J Urol 1998;159:297-303.
20. 2+ and extracellular protease inhibitors. Eur J Biochem 1999;262:781-9.
21. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998;34:44-50.
22. Christensen SB, Andersen A, Kromann H, et al. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999;7:1273-80.
23. Jakobsen CM, Denmeade SR, Isaacs JT, et al. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001;44:4696-703.
24. Denmeade SR, Lou W, Lovgren J, et al. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-30.
25. Khan SR, Denmeade SR. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 2000;45:80-3.
26. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999;20:348-55.
27. Mikolajczyk SO, Millar LS, Marker KM, et al. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem 1997;246:440-6.
28. Lovgren J, Tian S, Lundwall A, Karp M, Lilja H. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem 1999;266:1050-5.
29. Kramer A, Reineke U, Dong L, et al. Spot synthesis: observations and optimizations. J Pept Res 1999;54:319-27.
30. St Hilaire PM, Willert M, Juliano MA, Juliano L, Meldal M. Fluorescence-quenched solid phase combinatorial libraries in the characterization of cysteine protease substrate specificity. J Comb Chem 1999; 1:509-23.
31. Chan WC, White PD, editors. Fmoc solid phase peptide synthesis, a practical approach. New York: Oxford University; 2000.
32. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970;34:595-8.
33. Felix AM, Jimenez MH. Rapid fluorometric detection for completeness in solid phase coupling reactions. Anal Biochem 1973;52:377-81.
34. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Aced Sci U S A 1985; 82:5131-5.
35. Thorpe DS, Walle S. Combinatorial chemistry defines general properties of linkers for the optimal display of peptide ligands for binding soluble protein targets to TentaGel microscopic beads. Biochem Biophys Res Commun 2000;269:591-5.
36. Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/mL. Prostate 2001;49:101-9.
37. Denmeade SR, Sokoll LJ, Dalrymple S, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54:249-57.
38. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000;291:113-35.
39. Cloutier SM, Chagas JR, Mach JP, Gygi CM, Leisinger HJ, Deperthes D. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur J Biochem 2002;269:2747-54.
40. Schwaab R, Ludwig M, Kochhan L, et al. Detection and characterization of two missense mutations at a cleavage site in the factor VIII light chain. Thromb Res 1991;61:225-34.
41. Grzonka Z, Kasprzykowski F, Lubkowska L, Darlak K, Hahn TA, Spatola AF. In vitro degradation of some arginine-vasopressin analogs by homogenates of rat kidney, liver and serum. J Pept Res 1991;4:270-4.
42. Kumar A, Mikolajczyk SD, Hill TM, Millar LS, Saedi MS. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate 2000;44:248-54.